drugset / Trial / NCT00141258

Pregabalin Epilepsy Add-On Trial

NCT00141258

Phase 3 Completed 178 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures

Timeline

Start
2005-10
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule

Indications